These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 19900256)

  • 1. Using the Rasch model to validate and enhance the interpretation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index--Disease-Related Symptoms scale.
    Luo X; Cappelleri JC; Cella D; Li JZ; Charbonneau C; Kim ST; Chen I; Motzer RJ
    Value Health; 2009 Jun; 12(4):580-6. PubMed ID: 19900256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.
    Cella D; Li JZ; Cappelleri JC; Bushmakin A; Charbonneau C; Kim ST; Chen I; Motzer RJ
    J Clin Oncol; 2008 Aug; 26(22):3763-9. PubMed ID: 18669464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Important Group Differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma.
    Cella D; Motzer RJ; Rini BI; Cappelleri JC; Ramaswamy K; Hariharan S; Arondekar B; Bushmakin AG
    Value Health; 2018 Dec; 21(12):1413-1418. PubMed ID: 30502785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma.
    Cella D; Bushmakin AG; Cappelleri JC; Charbonneau C; Michaelson MD; Motzer RJ
    Br J Cancer; 2012 Feb; 106(4):646-50. PubMed ID: 22240794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis.
    Cella D; Michaelson MD; Bushmakin AG; Cappelleri JC; Charbonneau C; Kim ST; Li JZ; Motzer RJ
    Br J Cancer; 2010 Feb; 102(4):658-64. PubMed ID: 20104222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.
    Cella D; Grünwald V; Nathan P; Doan J; Dastani H; Taylor F; Bennett B; DeRosa M; Berry S; Broglio K; Berghorn E; Motzer RJ
    Lancet Oncol; 2016 Jul; 17(7):994-1003. PubMed ID: 27283863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of a scale to measure disease-related symptoms of kidney cancer.
    Cella D; Yount S; Brucker PS; Du H; Bukowski R; Vogelzang N; Bro WP
    Value Health; 2007; 10(4):285-93. PubMed ID: 17645683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma.
    Cella D; Davis MP; Négrier S; Figlin RA; Michaelson MD; Bushmakin AG; Cappelleri JC; Sandin R; Korytowsky B; Charbonneau C; Matczak E; Motzer RJ
    Cancer; 2014 Jun; 120(12):1871-80. PubMed ID: 24634003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma.
    Trask PC; Bushmakin AG; Cappelleri JC; Tarazi J; Rosbrook B; Bycott P; Kim S; Stadler WM; Rini B
    J Cancer Surviv; 2011 Sep; 5(3):255-62. PubMed ID: 21476015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.
    Cella D; Escudier B; Tannir NM; Powles T; Donskov F; Peltola K; Schmidinger M; Heng DYC; Mainwaring PN; Hammers HJ; Lee JL; Roth BJ; Marteau F; Williams P; Baer J; Mangeshkar M; Scheffold C; Hutson TE; Pal S; Motzer RJ; Choueiri TK
    J Clin Oncol; 2018 Mar; 36(8):757-764. PubMed ID: 29377755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).
    Cella D; Yount S; Du H; Dhanda R; Gondek K; Langefeld K; George J; Bro WP; Kelly C; Bukowski R
    J Support Oncol; 2006 Apr; 4(4):191-9. PubMed ID: 16669463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer.
    Bukowski R; Cella D; Gondek K; Escudier B;
    Am J Clin Oncol; 2007 Jun; 30(3):220-7. PubMed ID: 17551296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population.
    Castellano D; del Muro XG; Pérez-Gracia JL; González-Larriba JL; Abrio MV; Ruiz MA; Pardo A; Guzmán C; Cerezo SD; Grande E
    Ann Oncol; 2009 Nov; 20(11):1803-12. PubMed ID: 19549706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comparison of the Renal Cell Carcinoma-Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).
    Rao D; Butt Z; Rosenbloom S; Robinson D; Von Roenn J; Kuzel TM; Cella D
    J Pain Symptom Manage; 2009 Aug; 38(2):291-8. PubMed ID: 19356897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma.
    Remák E; Charbonneau C; Négrier S; Kim ST; Motzer RJ
    J Clin Oncol; 2008 Aug; 26(24):3995-4000. PubMed ID: 18711190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
    JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
    Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
    Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
    Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
    Park CY
    Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
    Siebels M; Staehler M; Hegele A; Varga Z; Oberneder R; Doehn C; Heinzer H;
    Aktuelle Urol; 2010 Mar; 41(2):122-30. PubMed ID: 19937556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.